Literature DB >> 20378710

Reduction of MPO-ANCA epitopes in SCG/Kj mice by 15-deoxyspergualin treatment restricted by IgG2b associated with crescentic glomerulonephritis.

Kazuo Tomizawa1, Tomokazu Nagao, Reina Kusunoki, Kan Saiga, Masamichi Oshima, Kazuo Kobayashi, Toshinori Nakayama, Masaru Tanokura, Kazuo Suzuki.   

Abstract

OBJECTIVES: The MPO-specific antineutrophil cytoplasmic antibodies (MPO-ANCA) are associated with renal failure. Epitopes of MPO-ANCA and immunoglobulin G (IgG) subclass and cytokine levels in the recovery phase were analysed by the administration of 15-deoxyspergualin (DSG) to SCG/Kj mice, which show spontaneous crescentic GN (CrGN).
METHODS: We treated SCG/Kj mice by using DSG and MPO deletion mutants to investigate epitopes of MPO-ANCA associated with renal failure in SCG/Kj mice. After DSG treatment for 30 days, we observed histological changes in a crescentic formation and infiltration of neutrophils and lymphocytes into kidney, cytokines/chemokines and MPO-ANCA epitopes by deletion mutants.
RESULTS: MPO-ANCA were reduced by the administration of DSG, and epitopes of MPO-ANCA, mainly H-6, decreased. Moreover, the IgG2b subclass of the H-6 epitope of MPO-ANCA was greatly decreased by DSG treatment. These observations correlated with a decrease in renal failure and proteinuria, infiltration of neutrophils and lymphocytes into glomeruli, and crescent formation. The CD4/CD8 ratio of splenocytes ranged from 1.68 (0.24) in the non-treated group to 0.90 (0.12) at 100 microg/mouse/day in the DSG-treated group. In addition, elevated levels of IL-12p40, IL-10 and IL-13 in the active phase of CrGN clearly decreased with DSG treatment but not with TNF-alpha. In contrast, the IL-1alpha level increased, and IL-17 and IL-12p70 slightly increased with DSG treatment.
CONCLUSION: These results strongly suggest that DSG treatment of SCG/Kj mice leads to the reduction of risk antibodies in IgG2b and normalization of B-cell clones accompanied by recovery of the cytokine and chemokine balance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20378710     DOI: 10.1093/rheumatology/keq087

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  5 in total

Review 1.  Proposal of anti-moesin as a novel biomarker for ANCA-associated vasculitis.

Authors:  Kazuo Suzuki; Koya Suzuki; Tomokazu Nagao; Toshinori Nakayama
Journal:  Clin Exp Nephrol       Date:  2013-09-27       Impact factor: 2.801

2.  Remarks on the Asia Pacific Meeting of Vasculitis and ANCA Workshop 2012.

Authors:  Kazuo Suzuki
Journal:  Clin Exp Nephrol       Date:  2013-04-25       Impact factor: 2.801

3.  Mizoribine provides effective treatment of sequential histological change of arteritis and reduction of inflammatory cytokines and chemokines in an animal model of Kawasaki disease.

Authors:  Kei Takahashi; Toshiaki Oharaseki; Tomokazu Nagao; Yuki Yokouchi; Hitomi Yamada; Noriko Nagi-Miura; Naohito Ohno; Tsutomu Saji; Tomio Okazaki; Kazuo Suzuki
Journal:  Pediatr Rheumatol Online J       Date:  2011-09-29       Impact factor: 3.054

4.  Immunomodulation with eicosapentaenoic acid supports the treatment of autoimmune small-vessel vasculitis.

Authors:  Junichi Hirahashi; Kimito Kawahata; Makoto Arita; Ryo Iwamoto; Keiichi Hishikawa; Mie Honda; Yoshifumi Hamasaki; Mototsugu Tanaka; Koshu Okubo; Miho Kurosawa; Osamu Takase; Masanori Nakakuki; Kan Saiga; Kazuo Suzuki; Shoji Kawachi; Akihiro Tojo; George Seki; Takeshi Marumo; Matsuhiko Hayashi; Toshiro Fujita
Journal:  Sci Rep       Date:  2014-09-18       Impact factor: 4.379

5.  Efficacy of a recombinant single-chain fragment variable region, VasSF, as a new drug for vasculitis.

Authors:  Yosuke Kameoka; Fukuko Kishi; Minako Koura; Yoshio Yamakawa; Rora Nagasawa; Fuyu Ito; Junichiro Matsuda; Osamu Suzuki; Toshinori Nakayama; Kazuo Suzuki
Journal:  Drug Des Devel Ther       Date:  2019-02-05       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.